At a glance
ClinicalIndex Comparison RecordN/ACompleted· 42 enrolled
Drug / intervention
Xyntha : coagulation factor IIIV (recombinant)drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Post Marketing Surveillance To Observe Safety And Efficacy Of Xyntha 'Registered' In Subjects With Hemophilia A
In Brief
An observational study evaluating Xyntha : coagulation factor IIIV (recombinant) for Hemophilia A. Completed, enrolled 42 participants across 4 sites.
Detailed Summary
This study is to describe the safety and efficacy of Xyntha® during the usual care setting.
Study Details
Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsHemophilia A
CountriesSouth Korea
Collaborators--
Timeline
N/ACompletedFinished
20132014201520162017201820192020202120222023202420252026
First PostedFeb 2013
Enrollment StartFeb 2014
Primary CompletionAug 2014
TodayJul 2026
First PostedFeb 13, 2013
Enrollment StartFeb 1, 2014
Primary CompletionAug 1, 2014
TodayJul 2, 2026
Enrollment to primary: 6 monthsPosted 13.4 years ago
Interventions
Xyntha : coagulation factor IIIV (recombinant)drug
Xyntha will be administered according to physician's discretion.